In the continuous effort to develop even more selective and effective NOS2 inhibitors, different acetamidines structurally related to the 1400W leading scaffold have been published [31,34,35,36,37], thus confirming the growing interest in the pharmacologic potential of NOS2 activity inhibition in different diseases, including GBM. Here, NOS2 is linked to glioblastoma.